Present status and prospects for chemotherapy for advanced or recurrent gastric cancer in our hospital

Manabu Yamamoto, Ayumi Matsuyama, Yasunori Emi, Shuya Yano, Toshifumi Kameyama, Masahiro Okamoto, Sosei Kuma, Tohru Utsunomiya, Teruyoshi Ishida

Research output: Contribution to journalArticle

Abstract

Since S-1 was approved in 1999, the response rate and the disease control rate of the chemotherapy for advanced or recurrent gastric cancer have improved. It is important to perform chemotherapy using key drugs and to plan the chemotherapy for each case. Of the 32 patients in our hospital, the median survival time (MST) was 21 months for chemotherapy in advanced or recurrent gastric cancer during 2003-2006. MST for patients who had up to second- or third-line treatment was longer than for patients with up to first-line treatment. In addition, it there was no difference in prognosis for patients using CPT-11 or taxane at second-line after using S-1 at first-line treatment. The first-line chemotherapy for advanced or recurrent gastric cancer should be decided by the disease condition of each patient and the characteristics of each anti-cancer drug. In addition, the prognosis of patients will improve if second- or third-line chemotherapy can be performed.

Original languageEnglish
Pages (from-to)441-444
Number of pages4
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume35
Issue number3
Publication statusPublished - Mar 2008
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Present status and prospects for chemotherapy for advanced or recurrent gastric cancer in our hospital'. Together they form a unique fingerprint.

  • Cite this

    Yamamoto, M., Matsuyama, A., Emi, Y., Yano, S., Kameyama, T., Okamoto, M., Kuma, S., Utsunomiya, T., & Ishida, T. (2008). Present status and prospects for chemotherapy for advanced or recurrent gastric cancer in our hospital. Gan to kagaku ryoho. Cancer & chemotherapy, 35(3), 441-444.